Canada - English - Health Canada

teva canada limited - everolimus - tablet - 10mg - everolimus 10mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - everolimus - tablet - 7.5mg - everolimus 7.5mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharmaceuticals limited - glatiramer acetate - solution for injection - 20 mg/ml - other immunostimulants

Canada - English - Health Canada

teva canada limited - valsartan; hydrochlorothiazide - tablet - 80mg; 12.5mg - valsartan 80mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

teva canada limited - valsartan; hydrochlorothiazide - tablet - 160mg; 12.5mg - valsartan 160mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

teva canada limited - valsartan; hydrochlorothiazide - tablet - 160mg; 25mg - valsartan 160mg; hydrochlorothiazide 25mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

teva canada limited - valsartan; hydrochlorothiazide - tablet - 320mg; 12.5mg - valsartan 320mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

teva canada limited - valsartan; hydrochlorothiazide - tablet - 320mg; 25mg - valsartan 320mg; hydrochlorothiazide 25mg - angiotensin ii receptor antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 18.15 mg - capsule - excipient ingredients: microcrystalline cellulose; indigo blue; titanium dioxide; croscarmellose sodium; gelatin; purified talc; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 12.1 mg - capsule - excipient ingredients: colloidal anhydrous silica; gelatin; croscarmellose sodium; iron oxide yellow; purified talc; microcrystalline cellulose; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.